Talking Immunization with your Adult Patients

Practical Strategies for Overcoming Barriers

Jointly provided by Center for Independent Healthcare Education and Vemco MedEd

Supported by an educational grant from Merck & Co.
Call-to-Action: Recognizing the Burden of Vaccine-Preventable Diseases

Thomas M. File, Jr., MD, MS, MACP, FIDSA, FCCP
Chair, Infectious Disease Division
Summa Health System
Akron, OH
Professor, Internal Medicine
Master Teacher; Chair, Infectious Disease Section
Northeast Ohio Medical University
Rootstown, OH
Past President, NFID
Bethesda, MD
Impact of Vaccines

• Vaccines are one of the most important tools we have to protect the health of our nation’s citizens.

• In last 100 years, the lifespan of Americans has doubled; largely as a result of vaccines and sanitation.
Burden of Vaccine-Preventable Diseases

Each Year

- 226,000 hospitalizations due to influenza
  - As many as 49,000 deaths
- 32,000 cases of invasive pneumococcal disease
  - Approximately 3,000 deaths
- Over 1 million people suffer from chronic hepatitis B
- Over 1 million people develop shingles
- 17,000 cancers in women and 9,000 cancers in men are caused by HPV

CDC Vaccine Information for Adults. http://www.cdc.gov/vaccines/adults/vpd.html
### Economic Burden

<table>
<thead>
<tr>
<th>Disease</th>
<th>Probability of hospitalization</th>
<th>No. of hospitalization days</th>
<th>Cost per hospitalization</th>
<th>Cost per outpatient visit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pertussis</td>
<td>0.65–30%</td>
<td>16.7</td>
<td>$102,584</td>
<td>$100–$173</td>
</tr>
<tr>
<td>Measles</td>
<td>11–100%</td>
<td>1.3–10.9</td>
<td>$4,032–$46,060</td>
<td>$88–$526</td>
</tr>
<tr>
<td>Hepatitis B</td>
<td>0.001–100%</td>
<td>3.9–11</td>
<td>$15,662–$27,051</td>
<td>$214–$599</td>
</tr>
<tr>
<td>Pneumococcal Disease</td>
<td>0–100%</td>
<td>6.4–16.8</td>
<td>$3,798–$25,848</td>
<td>$86–$272</td>
</tr>
</tbody>
</table>

For each birth cohort vaccinated:

- 42,000 lives saved
- 20 million cases of disease prevented
- 13.6 billion dollars saved in direct costs
- 69 billion dollars saved total (with indirect cost)
- For each dollar spent, $10.20 saved

Threats to Vaccines

• Falling rates
• Success of past vaccines
  – Lack of awareness of disease that is prevented
• Effects of anti-vaccine movement
  – Fear, mistrust, ignorance
Consequences of Lapse on Immunization: Outbreaks

• California (2010)
  • 9,143 cases of pertussis (including ten infant deaths) were reported throughout California. Most cases reported in 63 years.
  • Measles outbreak source

• Ohio (2010-2014)
  – In 2010, there were 964 cases of pertussis reported by Columbus and Franklin Counties. Most cases reported in 25 years.
  – In 2014, there have been 377 cases of measles (10 hospitalized) since March.
  – In 2014, there have been 460 cases of mumps (many linked to OSU) since Jan.
2013 Adult Immunization Coverage, US

**Influenza Estimates 2013-14.

MMWR. Feb 6, 2015. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6404a6.htm#Tab2
Issues with Adult Vaccination

- Busy Practice
- Costly Inventory
- Storage and Handling Concerns
- Frequently Changing Practice Guidelines
- Lack of System-wide Documentation
- Inconsistent Reimbursement
- Patient Objections/Myths
Recent Survey Indicates Miscommunication Between Physicians and Patients

Most physicians say “I talk to all of my patients about vaccines”

Physicians
Survey respondents:
Consumers, N = 1,013; physicians, N = 300 PCPs.

Patients
Survey respondents:
Consumers, N = 1,013; physicians, N = 300 PCPs.

An additional 26% say they only ever discuss influenza vaccine.

Physicians

But few patients agree

“Yes, I regularly discuss vaccines with my HCP”
18%

“I occasionally discuss vaccines with my HCP”
31%

“I don’t recall ever discussing vaccines”
21%
The Communications Breakdown

Recommendation

"You need to get this vaccine." OR "I want you to get this vaccine." = Vaccine-Motivated Patient

Not a Recommendation

"Do you want this vaccine?" OR "Think about getting the vaccine." = Vaccine-Ambivalent Patient
Best Practices in Vaccine-Preventable Diseases: Pneumococcal Disease

Michael D. Hogue, PharmD, FAPhA, FNAP
Professor and Chair
Department of Pharmacy Practice
Samford University
McWhorter School of Pharmacy
Birmingham, AL
42-year-old woman with asthma and HTN who presents for a preventive health visit. Her asthma is controlled on montelukast and an inhaled steroid. She received influenza vaccination in October. Which of the following is the best assessment/recommendation for pneumococcal immunization of Jane?

1. AVERAGE RISK: NO pneumococcal immunization  
2. INTERMEDIATE RISK: PCV13 only  
3. INTERMEDIATE RISK: PPSV23 only  
4. HIGH RISK: PPSV23 today, PCV13 1 yr.  
5. HIGH RISK: PCV13 today, PPSV23 1 yr.
[Jane’s father] is a healthy 67-year-old man who comes in for a wellness visit. He smokes 3 cigars a week and has no medical conditions. He received high-dose influenza vaccine from his local pharmacy in September. Which of the following is the best assessment/recommendation for pneumococcal immunization of Jon?

1. AVERAGE RISK: NO pneumococcal immunization
2. INTERMEDIATE RISK: PCV13 only
3. INTERMEDIATE RISK: PPSV23 only
4. HIGH RISK: PPSV23 today, PCV13 1 yr.
5. HIGH RISK: PCV13 today, PPSV23 1 yr.
Pneumococcal Disease Pathogenesis and Burden in Adults Aged ≥50 Years

The Incidence Rate of Pneumococcal Disease Increases With Age and Certain Chronic Conditions

Incidence Rate of IPD — United States, 1999–2000

- **Chronic heart disease**
- **Chronic lung disease**
- **Diabetes mellitus**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Risk Factor</th>
<th>Compared to Healthy Adults</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes mellitus</td>
<td>3X</td>
<td>compared to healthy adults</td>
</tr>
<tr>
<td>Chronic heart disease</td>
<td>6X</td>
<td>compared to healthy adults</td>
</tr>
<tr>
<td>Chronic lung disease</td>
<td>6X</td>
<td>compared to healthy adults</td>
</tr>
</tbody>
</table>

IPD, invasive pneumococcal disease.
Pneumococcal Vaccines

- **PPSV23**
  - Purified capsular polysaccharide→ ‘traditional’ PNC vaccine
  - Contains 23 types—cause ~88% bacteremic pneumococcal disease
  - 60%–70% effectiveness vs. invasive disease
    - Challenge to assess prevention of PNC pneumonia.
  - Immunity lasts at least 5 years following 1 dose
  - FDA-approved for all persons ≥2 years at increased risk for pneumococcal disease
  - Local reactions – only common adverse event

- **PCV13**
  - Conjugate vaccine-more immunogenic
  - Replaced PCV7 for childhood immunization [6 wk–6 yr] in 2010
  - 2011 FDA-approved for adults >50 years: prevent pneumonia, IPD
    - Based on immunogenicity and safety studies
  - 2012 ACIP recommends PCV: IPD prevention, highest-risk adults
    - Highest risk based on anatomic and immunocompromised
    - Best practice: give BEFORE PPSV23
  - 2014 ACIP recommends PCV/PPS combination strategy in aged 65+
  - Local reactions – only common adverse event

In 2013, 38% of IPD among adults aged ≥65 years was caused by serotypes unique to PPSV23

PPSV23 Vaccine Effectiveness

• What is the evidence in preventing IPD and pneumonia?
  – Meta-analysis including 18 RCTs (64,852 participants)

<table>
<thead>
<tr>
<th>Event</th>
<th>No. of RCTs</th>
<th>Event with Vaccine (n/N)</th>
<th>Event with Control (n/N)</th>
<th>OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IPD</td>
<td>11</td>
<td>15/18634</td>
<td>63/17855</td>
<td>0.26 (0.14 to 0.45)</td>
</tr>
<tr>
<td>IPD (vaccine types only)</td>
<td>5</td>
<td>14/13889</td>
<td>140/17334</td>
<td>0.18 (0.10 to 0.31)</td>
</tr>
<tr>
<td>Pneumonia (all causes)</td>
<td>16</td>
<td>978/22643</td>
<td>1547/25091</td>
<td>0.72 (0.56 to 0.93)</td>
</tr>
<tr>
<td>Definitive pneumococcal pneumonia</td>
<td>10</td>
<td>15/18132</td>
<td>60/17351</td>
<td>0.26 (0.15 to 0.46)</td>
</tr>
<tr>
<td>Definitive pneumococcal pneumonia (vaccine types only)</td>
<td>4</td>
<td>3/15583</td>
<td>30/14978</td>
<td>0.13 (0.05 to 0.38)</td>
</tr>
</tbody>
</table>

Protective vaccine efficacy for definitive pneumococcal pneumonia: 74% (95% CI, 54%–85%)

PCV13 Adult Vaccine Effectiveness

CAPiTA

- Placebo Controlled RCT PCV13 unimmunized adults 65+ years
  - Netherlands
    - No routine pneumococcal vaccine in adults
    - PCV7 in Dutch infants since 6/2006 -> PCV10 in March 2011
- 84,000+ participants PCV13 vs. Placebo
- Outcomes:
  - Primary: Reduced 1st bacteremic CAP with vaccine-type PNC
  - Secondary: Reduced 1st nonbacteremic CAP
- Serologic and urinary Ag used to identify PNC infection
- Considered by ACIP Pneumococcal group 2014
- DID NOT address sequential PCV13/PPSV23 immunization

## Pneumococcal Immunization

### PPSV23 ALONE for **INCREASED RISK**

<table>
<thead>
<tr>
<th>All cigarette smokers ≥19 yo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic conditions ≥19 yo:</td>
</tr>
<tr>
<td>Diabetes</td>
</tr>
<tr>
<td>Lung disease: asthma, COPD</td>
</tr>
<tr>
<td>Cardiovascular disease</td>
</tr>
<tr>
<td>Liver disease</td>
</tr>
<tr>
<td>Kidney disease</td>
</tr>
<tr>
<td>(except ESRD, nephrotic – HIGHEST risk)</td>
</tr>
</tbody>
</table>

- **REVACCINATION ONCE** after age 65 [PLUS 5 years after initial dose] for those vaccinated prior to age 65
- Adults 65 years and older: now in highest risk group.

http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5934a3.htm
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6140a4.htm
# Pneumococcal Immunization II

**SEQUENTIAL PCV13 + PPSV23: HIGHEST RISK**

**Immunocompromised:**

1. **Disease:**
   - Cancer: solid tumors, hematologic malignancies, myeloma, etc.
   - HIV
   - INHERITED and OTHER immune deficiency (CVID, etc.)
   - End-stage kidney disease (ESRD), nephrotic syndrome

2. **Iatrogenic:**
   - MEDS: Steroids (20+ mg/d), biologic immunomodulators, others
   - TRANSPLANTS: solid organ, bone marrow, stem cell

3. **Asplenia:**
   - ANATOMIC: splenectomy (best if immunized prior to)
   - FUNCTIONAL: hemoglobinopathy, sickle cell, other

**Anatomic:**

- CSF leak, cochlear implant, splenectomy

**Age:** Adults 65 and older

http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6140a4.htm
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6337a4.htm
Pneumococcal vaccination for those ≥65 years of age

• For those who have yet to receive any pneumococcal vaccine:
  – Administer PCV13 followed by PPSV23 in ≥1 year

• For those who were previously vaccinated with PPSV23:
  • Administer PCV13 ≥1 year from PPSV23 vaccination
Best Practices in Vaccine-Preventable Diseases: Pertussis

Thomas M. File, Jr., MD, MS, MACP, FIDSA, FCCP
Chair, Infectious Disease Division
Summa Health System
Akron, OH
Professor, Internal Medicine
Master Teacher; Chair, Infectious Disease Section
Northeast Ohio Medical University
Rootstown, OH
Past President, NFID
Bethesda, MD
PN, 65-yo male presents with a three-week h/o nonproductive cough which occurs more frequently at night. He reports that initially he had “a cold” (coryza, sneezing, mild cough) but has never had a fever. OTC dextromethorphan has not provided relief. He tries to keep a cough drop in his mouth at bedtime. Humidified air and hot showers provide some temporary relief. The cough has gotten worse, and last evening he vomited after a severe coughing episode.
Bordetella pertussis

- Gram-negative
- Produces at least 6 antigenic and biologically active products
- Considered primarily a toxin-mediated disease
- Requires special media for isolation/culture
  - Properly conducted nasopharyngeal swab
- Attaches and paralyzes cilia

Pertussis

“Bordetella pertussis is the most poorly-controlled bacterial vaccine-preventable disease in the U.S., with peaks in disease occurring every 3–5 years…Notable peaks in disease occurred in 2004 (25,827 cases, 27 deaths), 2010 (27,550 cases, 27 deaths), and most recently in 2012 when more than 41,000 cases and 18 deaths were reported, the largest number of cases in the U.S. since 1959.”

Pertussis

• Reservoir
  – Adolescents and adults are important sources of infection for infants

• Transmission
  – Person-to-person through contact with respiratory droplets generated by coughing and sneezing

• Highly communicable
  – Patients are most infectious during the catarrhal and early paroxysmal phases of illness and can remain infectious for ≥6 weeks or for 5 days after initiating appropriate antimicrobial therapy.

Disease Progression:

**Weeks**

<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>11</th>
<th>12</th>
</tr>
</thead>
</table>

**Stage 1 - Catarrhal Stage**
May last 1 to 2 weeks

- Symptoms: runny nose, low-grade fever, mild, occasional cough
- Highly contagious

**Stage 2 - Paroxysmal Stage**

- Lasts from 1-6 weeks; may extend to 10 weeks

- Symptoms: fits of numerous, rapid coughs followed by "whoop" sound; vomiting and exhaustion after coughing fits (called paroxysms)

**Stage 3 - Convalescent Stage**

- Lasts about 2-3 weeks; susceptible to other respiratory infections for many

- Recovery is gradual. Coughing lessens but fits of coughing may return.
Pertussis Treatment

- Treatment should occur as early as possible.
- Treat prior to test results if clinical history is strongly suggestive or if patient is at risk of severe or complicated disease.
- Treatment with
  - azithromycin (5 day course)
  - clarithromycin (7 day course)
  - erythromycin (14 day course)
  - *alternatively trimethoprim-sulfamethoxazole (14-day course).
- All household contacts should be treated even if asymptomatic within 21 days of exposure.
- Treat high-risk non-household contacts. Consult current recommendations for specific populations.

2005 CDC Guidelines for Treatment and Post-Exposure Prophylaxis.
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5414a1.htm
Burden of Disease

Pertussis Cases, United States, 1927-2014

http://www.cdc.gov/pertussis/surv-reporting/cases-by-year.html
Vaccines

- **DTaP**
  - 5 doses for children 2 months through 6 years of age
- **Tdap**
  - 1 dose for those 11 years and older
    (Preferably at 11 or 12 years of age)
  - 1 dose for pregnant women during each pregnancy, preferably administered at 27 to 36 weeks gestation.
Tdap Vaccine

• Contraindications:
  – Serious (e.g. anaphylaxis) ADR to a previous dose OR encephalopathy within 7 days following a previous pertussis-antigen dose.

• Precaution:
  – Defer vaccination in patients with unstable or progressive neurologic conditions.

• Safety
  – Most common ADEs are injection site related (Nearly $\frac{3}{4}$ of patients)
    • Pain, erythema, swelling
  – Systemic effects include headache and fatigue
  – Fever is relatively uncommon (1:10) compared to older DTwP (9:10).

CDC. ACIP Recommendations, Tdap and Td Vaccines. 2010.
Special Considerations

- DTaP and Tdap vaccines are covered under the VFC program for children up to 18 years of age.
- Medicare Part D covered by most plans
- ACA requires ACIP-recommended vaccines be covered under newly issued plans/policies
Best Practices in Vaccine-Preventable Diseases: Herpes Zoster

Robert H. Hopkins, Jr., MD, FACP, FAAP
Professor of Internal Medicine and Pediatrics
Director, Division of General Internal Medicine
Program Director, Med-Peds Residency
UAMS College of Medicine
Little Rock, AR
Healthy 67-year-old man who returns for wellness visit. He smokes 3 cigars a week and had an episode of shingles 5 months ago. He received high-dose influenza vaccine from his local pharmacy in September and pneumococcal vaccine 1 year ago. Which of the following is the most correct regarding zoster immunization for Jon?

1. No Zoster vaccination; he had previous shingles
2. No Zoster vaccination today–cannot administer with PPSV23
3. Zoster vaccine today
4. Zoster vaccine today and booster vaccination in 5–10 years
Zoster

• Most who have varicella have Ab for life
  – Zoster occurs when cell-mediated immunity (CMI) surveillance declines
  – Reactivation or varicella exposure re-stimulates CMI
  – Cycle can repeat multiple times

• Lifetime risk of Zoster ~33%
  – By age 85: risk ~50%
  – PHN= most common AE
    • Up to 1/3 patients with Zoster
    • More common
      – >70 years with Zoster
      – Immunocompromised

• Vaccination stimulates CMI

PHN, postherpetic neuralgia.
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5705a1.htm
Zoster Pathophysiology

- Reactivation of a latent Varicella zoster virus
  - Promptly or decades after chickenpox
- Trigger factors
  - Reduced immunocompetence
  - Trauma
  - Normal aging
- Estimated 1 million cases annually in the US
- Adults at greatest risk:
  - Immunocompromised conditions (e.g., malignancy, HIV)
  - Taking immunosuppressive medications (e.g., steroids, rheumatoid arthritis meds)

Centers for Disease Control and Prevention. Shingles (Herpes Zoster). Available at: www.cdc.gov/shingles/about/overview.html
Herpes Zoster (Shingles)
Complications of Zoster

- Scarring and keloid formation; secondary skin infection of skin lesions
- Visceral zoster and encephalitis
- Corneal damage and blindness
- Pneumonia (viral or bacterial)
- Postherpetic neuralgia (PHN)
  - Pain in the dermatome of rash after rash heals
  - Criteria: 90 (or 120) days after rash onset
  - Pain can last months to years
  - As people get older, more likely to develop PHN and the pain is more likely to be severe

Centers for Disease Control and Prevention. Shingles (Herpes Zoster). Available at: [www.cdc.gov/shingles/about/overview.html](http://www.cdc.gov/shingles/about/overview.html)
Duration of Pain after Rash Heals Increases With Age

Patient with post-rash Pain (%)

Age (years)

<20 20-29 30-39 40-49 50-59 60-69 >70

>1 year
6-12 mo
1-6 mo

de Moragas JM, Kierland RR. *AMA Arch Derm.* 1957;75:193-196.
Zoster

Vaccine Efficacy Trial:

– 38,546 Veterans: Median age: 69 years
  • 60–69 years: 20,747 [Efficacy greatest in this group]
  • ≥70 years: 17,799 (46%)
  • ≥80 years: ~2,500 (6.5%)
  • Excluded: Immunocompromised, prior zoster, <60 yrs.

– Vaccine group had [vs. placebo]:
  • 51% fewer episodes of zoster
  • Less severe disease
  • 66% less postherpetic neuralgia

– No significant safety issues were identified

Zoster

- Vaccinate HEALTHY adults 60+ years old
- **ACIP: NOT IMMUNOCOMPROMISED**
  - FDA-approved from age 50 differs from ACIP recommendation
  - Regardless of prior Zoster [arbitrary CDC opinion: wait 1 year]
  - No need to test/vaccinate vs. varicella first
- Contraindications
  - Pregnancy
  - Anaphylactic hypersensitivity to neomycin, gelatin
  - No need to defer for ‘at-risk contacts’—transmission risk low
  - No need to defer if recent transfusion, Ab-containing products
- Adverse events
  - Occasional mild varicella-like rash at vaccine site
- Frozen vaccine: Give w/in 60 minutes, 0.65 mL SQ deltoid
- Duration of protection: At least 4 years. No booster.

[Link to CDC website for more information](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5705a1.htm)
Zoster: Special Populations

- **Prior to Immune Suppression**
  - American College of Rheumatology recommends Zoster vaccine [2008] in age 50+ years
  - Recommend **off IS** ×4 weeks after vaccine
  - Poster ACR 2014:
    - Zoster vaccine in 57 patients on biologics SQ, IV
    - NO disseminated Zoster
    - Study ongoing…

- **HIV**
  - No recommendation for vaccination
  - Studies of vaccination in immune-reconstituted HIV patients are underway

- **No Publication Data:**
  - Revaccination, vaccination before age 50 years

Zoster: Special Consideration

- Simultaneous administration of pneumococcal vaccine
  - One study showed the average titer against varicella zoster virus (VZV) was lower in persons who received zoster and PPSV at the same visit compared to persons who received these vaccines 4 weeks apart.
  - However, a large study was subsequently conducted that showed that zoster vaccine was equally effective at preventing herpes zoster whether it was administered simultaneously with PPSV or 4 weeks earlier.
  - CDC continues to recommend that HZV and PPSV be administered at the same visit if the person is eligible for both vaccines.

www.cdc.gov/vaccines/vpd-vac/shingles/hcp-vaccination.htm&ei=LkhCVdGNM47SoAT46oGQAg&usg=AFQjCNFngsWk1AJGJ7j82iBjA-2GCnYATw&bvm=bv.92189499,d.cGU (Mar 12, 2015)
General Practice Recommendations

Michael Donnelly, MD
Associate Professor
Departments of Medicine and Pediatrics
Georgetown University
Medstar Georgetown University Hospital
Washington, DC
Swimming Upstream in CA

Comparison of PBE Rate 2001/2002 and PBE Rate 2013/2014 across California. The maps show the percentage of exempions (

% Exemption 0 0.01 - 1 1.01 - 5 5.01 - 10 10.01 - 25 25.01 - 40

Key cities marked on the map include Redding, Sacramento, San Francisco, Los Angeles, and San Diego.
**Key Messages:**

- The vaccine cold chain is a temperature-controlled environment used to maintain and distribute vaccines in optimal condition.
- Monitor the temperature of your storage unit(s) regularly to assure that appropriate conditions are maintained.
- Take immediate corrective action when a storage unit temperature is outside the recommended range (Troubleshooting).
- Call the vaccine manufacturer for guidance.
- If you are a VFC provider or have other vaccines purchased with public funds, contact your immunization program.
- Vaccine appearance is NOT a reliable indicator that vaccines have been stored under appropriate conditions.
- Vaccine exposed to inappropriate temperatures that is inadvertently administered generally should be repeated. Contact your immunization program, vaccine manufacturer(s), or both for guidance.
Vaccine Storage Example

LAIV and IIV vaccine effectiveness among 2-18 yrs over 3 seasons, by influenza type/subtype

<table>
<thead>
<tr>
<th></th>
<th>H1N1pdm09</th>
<th>H3N2</th>
<th>B</th>
</tr>
</thead>
<tbody>
<tr>
<td>LAIV</td>
<td>8</td>
<td>63</td>
<td>59</td>
</tr>
<tr>
<td>IIV</td>
<td>188</td>
<td>30</td>
<td>39</td>
</tr>
</tbody>
</table>

Total, Flu + 184 188 493 596 472 544
Vaccinated, Flu + 24 28 48 151 33 105

MedImmune Study: Adjusted LAIV H1N1 Effectiveness by Shipment Group

- Not explained by any other study covariates
Real Life Handling Issue

Overall Summary

- Moderate/high effectiveness in children observed in 2010-11, 2011-12, 2012-13, 2013-14 for A/H3N2 and B strains and for all matched strains in prior studies

- Low effectiveness observed for A/California H1N1pdm09 strain in US in 2010-2011 (trivalent formulation) and 2013-2014 (quadrivalent formulation)
  - Issue is specific for A/California H1N1pdm09 LAIV
  - Issue may be US-specific as LAIV appeared effective in Canada in 2013-14

- Low effectiveness of A/California LAIV not explained by
  - Manufacturing, poor stability under recommended storage (36-46°F), antigenic mismatch, prior vaccination, pre-existing immunity, or vaccine strain interference

- A/California H1N1pdm09 strain has unique HA stalk sequence not seen in any previous LAIV strain that makes HA less stable
  - Reduces viral fitness and makes strain more vulnerable to heat degradation

- Vaccine shipping when outdoor temperatures are >80°F correlates with reduced effectiveness for A/California LAIV but not other LAIV strains

- Will replace A/California LAIV with an antigenically matched strain with a more stable HA protein and add HA stability criterion to future strain selection processes
Timing and Spacing of Doses

- Doses inside the minimum interval do not count!
  - 4-day grace period for all minimum intervals except for rabies vaccine
  - Some states have more stringent requirements: follow those if so

- Increasing the interval potentially delays complete protection; but never need to restart a series
  - Case in point: HPV vaccine
  - Exception: Oral typhoid vaccine
Combination Vaccines

- Reduce the number of injections
- Potentially improve coverage and compliance
- Potentially reduce costs for both providers and patients
- Downside: Difficult to isolate which antigen may have caused side effect in the event one occurs
- Accurate documentation is a must!
Immunosuppression and Vaccines

- Live vaccines should be administered ≥4 weeks prior to planned immunosuppression.
- Inactivated vaccines should be administered ≥2 weeks prior to planned immunosuppression.
- Specialists and primary care providers share responsibility for immunizing immunosuppressed patients and their family members.

2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host

Agreed with IDSA Except:
- Anti-B cell antibodies to vaccine
  - Wait for 6 months
- Solid organ transplantation rejection meds to vaccine
  - Wait 2 months
- Hematopoietic cell transplants are a separate case (2011 guidelines apply)

TAKE HOME POINTS

Per CDC:

ASSESS vaccination status of all patients in every clinical encounter

Strongly RECOMMEND vaccines that patients need

ADMINISTER needed vaccines or REFER to a provider who can vaccinate

DOCUMENT vaccines received by your patients

Talking Immunization with your Adult Patients

Practical Strategies for Overcoming Barriers

Jointly provided by Center for Independent Healthcare Education and Vemco MedEd

Supported by an educational grant from Merck & Co.